

The Global Harmonisation of Contamination Control Strategy Regulations and Enforcement

Holistic, risk-based contamination control and risk management expectations have evolved from a regional regulatory expectation to a globally recognised cornerstone of sterile pharmaceutical manufacturing. Regulatory authorities and standards organisations are increasingly converging on a risk-based, lifecycle approach to proactive contamination prevention, driven by the need to ensure product quality, patient safety, and supply continuity. Recent updates to key frameworks including ICH Q9(R1), EU GMP Annex 1, PIC/S PE 009, and WHO Technical Report Series (TRS) 1044 reflect a shared emphasis on end-to-end contamination control strategies that extend across facility design, manufacturing operations, supplier management, environmental monitoring, and ongoing process oversight.

This global harmonisation signals a shift away from traditional, compliance-focused assessments toward evaluations of how effectively manufacturers identify, mitigate, and continuously manage contamination risks throughout the product lifecycle. Regulatory inspections increasingly scrutinise the robustness of risk management practices, the effectiveness of supplier oversight programmes, the investigation of recurring deviations, and the scientific justification underpinning contamination control decisions. Concurrently, international standards and compendia bodies, including ISO and USP, are embedding lifecycle contamination control principles into evolving industry guidance, further reinforcing expectations for proactive, integrated quality systems.

As authorities worldwide adopt or align their good manufacturing practice (GMP) requirements with these emerging standards, the principles embodied in EU GMP Annex 1 are becoming a de facto global benchmark rather than a solely European regulation.

In recent years, global regulatory authorities have renewed their focus on patient safety by requiring enhanced risk mitigation from manufacturers. This focus has expanded beyond the finished product to both upstream (supplier

management, manufacturing, sterilisation, etc.) and downstream (distribution, lifecycle management, etc.) processes. International regulatory and standard updates worldwide are increasingly aligned around common principles, raising expectations for comprehensive, lifecycle based risk management and contamination control that apply broadly across markets.

Specifically, the convergence of key initiatives including implementation of International Council for Harmonization (ICH) Q9, Quality Risk Management (R1), and the harmonised adoption of EU GMP Annex 1; the Pharmaceutical Co-Operation Scheme (PIC/S) Guide to GMP for Medicinal Products (PE 009 17); and the World Health Organization (WHO) Technical Report Series 1044 Annex 2: WHO good manufacturing practices for sterile pharmaceutical products, have established a new global benchmark for sterile injectable drug manufacturing.^{1,2,3,4} These developments have substantially redefined best practices and generated industry wide ripple effects. Since their introduction, regulators have intensified scrutiny of supplier qualification, cGMP compliance, and the adequacy of investigations and effectiveness of corrective actions related to recurring contamination issues, with greater enforcement actions where deficiencies are observed.

EU GMP Annex 1 originated within specific European Union frameworks; however, it is now widely recognised as the new global standard for contamination control. While compliance to EU GMPs is already applicable to any global territory exporting to the EU, due to the harmonisation with the PIC/S and WHO, regulators internationally are increasingly expecting manufacturers to demonstrate alignment with these principles regardless of whether products are intended for the EU market. This alignment between the WHO, PIC/S and EU reflect a broader regulatory consensus that the contamination control and risk management principles articulated in EU GMP Annex 1 represent appropriate, modern expectations for sterile manufacturing globally. As a result, individual countries are increasingly codifying these requirements into national law or integrate them into local GMP regulations to make them enforceable. In terms of risk management, this was already an international inspection focus however,

the updated ICH Q9 has significantly shifted from an individual process/product driven checkbox toward driving organisations to identify, assess, justify, and continuously manage risks across the full product and global supply lifecycle regardless of jurisdictional origin of the product.

Since 2023, many countries/territories have already moved to strengthen their GMP frameworks by aligning national requirements with the contamination control and risk management principles established in ICH Q9(R1) and EU GMP Annex 1, either through direct adoption or through functionally equivalent national requirements. The current adoption status internationally includes the following:

- EU Member States – All EU member states are required to comply with EU GMP Annex 1.
- Non EU Countries Recognising EU GMP – Countries such as Canada, Iceland, Israel, Liechtenstein, New Zealand, Norway, Switzerland, Ukraine, and the United Kingdom formally recognise EU GMP compliance and therefore expect adherence to Annex 1 to utilise the international recognition schemes.
- PIC/S Adoption – Countries including Australia, Canada, Egypt, Indonesia, Hong Kong, Japan, Jordan, Saudi Arabia, Malaysia, Pakistan, Singapore, Taiwan, and Türkiye have issued national guidance adopting PIC/S PE 009 17.
- WHO Alignment – Countries such as Paraguay, Venezuela and others generally align GMP expectations with WHO guidelines.
- Equivalent Contamination Control Requirements – The United States, India, Eurasian Economic Union (EAEU) and China have not formally adopted EU or PIC/S guidance but have implemented or proposed comparable contamination control requirements within their national GMP frameworks.

In the United States, although not directly harmonised with EU GMP Annex 1, existing regulations, along with recently released guidance, stress the importance of contamination control principles such as robust risk management, the clinical impact

of particulate, and holistic mitigation plans.^{5,6,7} Specific to end-to-end risk management, the Food and Drug Administration (FDA) agency's view is clear with the adoption of ICH Q9 (R1), but risk is also woven into almost all recent guidance related to quality. For example, The FDA guidance Risk Management Plans to Mitigate the Potential for Drug Shortages (May 2022) notes, "Effective quality risk management can facilitate better, more informed decisions; can provide FDA with greater assurance that stakeholders understand and can manage the associated risks; and can potentially affect the extent and level of direct regulatory oversight."⁷ In practice, recent FDA Inspections and Warning Letters indicate expectations in line with this statement. Approximately 39% of all drug recalls from the FDA are related to visible foreign particulate.^{8,9} Heightened supplier qualification scrutiny is also evident since 2023, with emphasis on data reliability, cGMP compliance, and adequacy of qualification procedures.¹⁰

When FDA inspection data are isolated to regulations associated with sterility assurance, contamination control, investigations, laboratory controls, and container closure systems, a pronounced post-2023 increase is observed.¹¹ Following implementation of EU GMP Annex 1 in August 2023, Voluntary Action Indicated (VAI) findings increased from 104 in FY2023 to 172 in FY2025 (+65%), while Official Action Indicated (OAI) findings increased from 61 to 103 (+69%) over the same period. FY2026 year to date remains directionally consistent, with 66 VAI and 42 OAI findings already identified, although FY2026 should be interpreted cautiously because it represents partial-year data. The trend suggests heightened regulatory scrutiny of contamination control and sterility assurance systems, with deficiencies increasingly identified in inspection outcomes requiring regulatory action. The pattern is consistent with industry-wide challenges in meeting evolving Annex 1 expectations, particularly around investigations, microbiological control, and container-closure assurance.

Communication from the FDA emphasises not only the importance of contamination control but the real-life consequences of a manufacturer's inaction. The data suggest that FDA observations tied to Annex 1-adjacent topics are not merely routine inspection findings. Of the 220 target-regulation FDA Form 483s identified from FY2020 through FY2026, approximately one in five was followed by a Warning Letter.¹¹ This reinforces the regulatory importance of contamination control, sterility



assurance, laboratory controls, investigations, and container closure integrity as areas where inspectional findings may escalate beyond observation into formal enforcement action.

Expectations are clear from the FDA that manufacturers have a deep understanding of their end-to-end products, processes, and suppliers. Specifically, to particulate contamination, the agency expects manufacturers to conduct studies on particulate levels and understand the impact of every individual process step (e.g. handling, incoming materials, processing including sterilisation, etc.) that could lead to particulate generation.⁶ Overall, the main objective of US applicants is to gain agreement from the FDA that the evidence provided in their submission and/or pre-approval inspection substantiates that the target product is safe and effective. It is clear from all available communication and enforcement trends that the FDA views contamination control as a key part of that evidence.

In China, the National Medical Products Administration (NMPA) issued a revised draft of the Sterile Drug Annex to the GMP for Drugs (2010 Revision) in March 2025.¹² The draft largely aligns with EU GMP Annex 1 while incorporating regional and technical requirements, such as enhanced material transfer controls and references to national pharmacopoeia standards (e.g., steam sterilisation condensate meeting Chinese water for injection specifications). China has continued to update its GMP framework, including publication of the Pharmaceutical Packaging Materials Annex (No. 1, 2025),

reinforcing risk management expectations and regulatory enforcement.¹³ Finalisation of the Sterile Drug Annex is anticipated in the near term and underscores how Annex 1 principles are being globally embedded and adapted, reinforcing their relevance as international benchmarks rather than region specific requirements.

Beyond China, several countries including Algeria, Brazil, Iran, Lebanon, Mexico, North Macedonia, Serbia, and South Africa are proposing or consulting on the implementation of enhanced contamination control measures, signalling further global alignment by tightening of requirements in the coming years.


In parallel with regulatory changes, standard setting organisations are also undergoing revision. Recent updates include ISO 14644 5:2025, Cleanrooms and associated controlled environments, Part 5: Operations and proposed USP chapters addressing contamination control and particulate mitigation. These standards embed holistic risk management principles across the product lifecycle, from initial development and facility design to equipment selection, materials, manufacturing processes, packaging, labelling, and supplier management.

Across both regulations and standards, expectations now reinforce integral aspects for effective contamination control strategies including robustness of risk governance, organisational accountability, data-driven decision making, improved supplier oversight, deviation recurrence handling, and continual improvement mechanisms

Global Harmonization of Contamination Control Strategy Regulations, Guidance & Enforcement



Estimated Enforcement Timing	Regulation or Guidance Status
Current	Enforced
1-2 Years	Draft
3-5 Years	In Assessment



This analysis is provided solely as a courtesy and is an estimation based on information available at the time of preparation. It is the user's responsibility to interpret GMP regulations applicable to their business or offerings. West Pharmaceutical Services, Inc. and its affiliates do not assume any responsibility for the user's regulatory strategy, product classification, risk management activities, technical documentation, conformity assessment, or any determination regarding the applicability or interpretation of Annex I requirements.

Overall, in the relatively short period since these initiatives were introduced, enhanced lifecycle risk management and contamination control expectations are becoming firmly established as a global norm that extends beyond compliance with any single guideline or geographic region. For jurisdictions that already have these enhanced regulations in force, manufacturers must quickly adapt processes, quality culture and documentation to remain in compliance. For jurisdictions with regulations not yet in force, manufacturers that implement comprehensive, risk-based contamination control strategies and demonstrate sustained effectiveness through continuous improvement will be better positioned to meet regulatory expectations, maintain inspection readiness, and support reliable supply of sterile products in an increasingly harmonised regulatory environment.

REFERENCES

1. ICH Q9, Quality Risk Management, 18 January 2023
2. The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 1, Manufacture of Sterile Medicinal Products, 22 August 2022
3. Pharmaceutical Co-Operation Scheme (PIC/S) Guide to GMP for Medicinal Products (PE 009 17), 25 August 2023
4. World Health Organization (WHO) Technical Report Series 1044 Annex 2: WHO good manufacturing practices for sterile pharmaceutical products, 31 October 2022
5. FDA Guidance, Q9 (R1) Quality Risk Management, May 2023
6. FDA Guidance, Inspection of Injectable Products for Visible Particulates, Dec 2021
7. FDA Guidance, Risk Management to Mitigate the Potential for Drug Shortages, May 2022
8. U.S. Food and Drug Administration. Drug Recalls. Accessed February 2026.
9. U.S. Food and Drug Administration. Recalls for
10. Biologics. Accessed February 2026.
11. U.S. Food and Drug Administration. Warning Letters. Accessed July 2026.
12. U.S. Food and Drug Administration. Inspections Database. Accessed July 2026.
13. Public Opinions Solicitation of Department of Comprehensive Affairs, Planning, and Finance Affairs of the National Medical Products Administration for the Sterile Drug Annex of the Good Manufacturing Practice for Drugs (2010 Revision) (Exposure Draft), March 17, 2025
14. Announcement of the National Medical Products Administration on Issuing the Appendices for Pharmaceutical Excipients and Drug Packaging Materials and Containers of the Good Manufacturing Practice for Drugs (2010 Revision) (No.1, 2025), January 2, 2025



Lauren Orme

Lauren Orme has more than 24 years of experience in pharmaceutical packaging, medical devices, and analytical services. She leads Regulatory Affairs Intelligence and Policy at West Pharmaceutical Services, overseeing global regulatory monitoring and compliance activities. Previously, she held technical and commercial roles supporting customer adoption of West's products and services. Lauren holds a B.S. in Biology from West Chester University and is a PMP-certified professional.

